ORIGINAL RESEARCH article

Front. Immunol.

Sec. B Cell Biology

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1613879

This article is part of the Research TopicB-cell Engineering in Malignant and Non-Malignant DiseaseView all articles

Mouse B cells engineered to express an anti-HPV antibody elicit anti-tumor T cell responses

Provisionally accepted
Michal GubermanMichal Guberman1,2Guy BiberGuy Biber1Natalie ZeliksonNatalie Zelikson3Sharon ShavitSharon Shavit1Roy AvrahamRoy Avraham1Yaron VagimaYaron Vagima1,4Deby BublikDeby Bublik1Yael KatzYael Katz1Adi BarzelAdi Barzel1,2Leah KlapperLeah Klapper1Shmulik HessShmulik Hess1Alessio David NahmadAlessio David Nahmad1,5*
  • 1Tabby Therapeutics, Ness Ziona, Israel
  • 2The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
  • 3Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Tel Aviv, Israel
  • 4Israel Institute for Biological Research (IIBR), Ness Ziona, Central District, Israel
  • 5The Samueli Integrative Cancer Pioneering Institute, Petah Tikva, Israel

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Transplantation of engineered B cells has shown efficacy in HIV disease models. B cell engineering may also be utilized for treatment of cancer. Recent studies highlighted that the activity of B cells is associated with favorable clinical outcomes in oncology. In mice, polyclonal B cells were shown to elicit anti-cancer responses. As a potential novel cell therapy, we demonstrate that engineering B cells to target a tumor-associated antigen potentiates polyclonal anti-tumor responses. We observe that engineered B cells expressing an anti-HPV B cell receptor internalize the antigen to allow subsequent activation of oncoantigen-specific T cells. Secreted antibodies from engineered B cells form immune complexes which are taken up by antigen-presenting cells to further promote T cell activation. Engineered B cells hold potential as novel, multi-modal cell therapies and open new avenues in solid tumor targeting.

Keywords: B cell, antibody, Cancer, Cell therapy (CT), tertiary lymphoid structures

Received: 17 Apr 2025; Accepted: 12 Jun 2025.

Copyright: © 2025 Guberman, Biber, Zelikson, Shavit, Avraham, Vagima, Bublik, Katz, Barzel, Klapper, Hess and Nahmad. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Alessio David Nahmad, Tabby Therapeutics, Ness Ziona, Israel

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material